Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of Internal Medicine

• Publication date

  2018-01-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/M17-2073PMID 29297009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

  2018cited by this paper
• Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

  2017cited by this paper
• Nivolumab-Induced Granulomatous Inflammation of the Pleura.

  2017cited by this paper
• Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.

  2017cited by this paper
• Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report

  2017cited by this paper
• Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

  2017cited by this paper
• Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy

  2017cited by this paper
• Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity

  2017cited by this paper
• Anti‐PD1‐induced psoriasis: a study of 21 patients

  2017cited by this paper
• Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

  2017cited by this paper
• PD‐1 inhibitor‐associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation—Report of 4 cases

  2017cited by this paper
• Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

  2017cited by this paper
• The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis

  2017cited by this paper
• Pembrolizumab: a New Drug That Can Induce Exacerbations of Psoriasis☆

  2016cited by this paper
• Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

  2016cited by this paper
• Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

  2016cited by this paper
• The association between CTLA‐4 (+49 A/G) polymorphism and susceptibility to ankylosing spondylitis: a meta‐analysis

  2016cited by this paper
• Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).

  2016cited by this paper
• The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.

  2016cited by this paper
• Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma

  2016cited by this paper
• Vasculitic neuropathy induced by pembrolizumab.

  2016cited by this paper
• Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis

  2016cited by this paper
• Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

  2016cited by this paper
• Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease

  2016cited by this paper
• CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

  2016cited by this paper
• Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

  2016cited by this paper
• Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab

  2016cited by this paper
• Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab.

  2016cited by this paper
• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

  2016cited by this paper
• Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

  2016cited by this paper
• Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.

  2016cited by this paper
• Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

  2016cited by this paper
• Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab

  2016cited by this paper
• Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases

  2016cited by this paper
• Myasthenia gravis exacerbation associated with pembrolizumab

  2016cited by this paper
• A Case of Myasthenia Gravis Exacerbation in a Patient with Melanoma Treated with Pembrolizumab (P3.138)

  2016cited by this paper
• Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer

  2016cited by this paper
• A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis

  2016cited by this paper
• Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

  2016cited by this paper
• Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Meta-analysis of genetic polymorphisms in programmed cell death 1 Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility

  2015cited by this paper
• Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

  2015cited by this paper
• Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis

  2015cited by this paper
• Ipilimumab in patients with melanoma and autoimmune disease

  2014cited by this paper
• Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

  2014cited by this paper
• Ipilimumab in a patient with known Crohn's disease: to give or not to give?

  2014cited by this paper
• Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

  2014cited by this paper
• Immune modulation in cancer with antibodies.

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis.

  2014cited by this paper
• The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis

  2014cited by this paper
• Kidney injuries related to ipilimumab

  2014cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy

  2013cited by this paper
• Ipilimumab-induced Colitis in a Patient with Ulcerative Colitis and Lung Cancer: 1361

  2013cited by this paper
• PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

  2012cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Guidelines for Submitting Adverse Event Reports for Publication

  2010cited by this paper
• CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

  2009cited by this paper
• Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis

  2009cited by this paper
• Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta‐analysis

  2009cited by this paper
• CTLA‐4: a key regulatory point in the control of autoimmune disease

  2008cited by this paper
• Guidelines for Submitting Adverse Event Reports for Publication

  2007cited by this paper
• Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus

  2004cited by this paper

• Immune Checkpoint Inhibitors are Associated with Peripheral Artery Disease in Cancer Patients.

  2026cites this paper
• Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease.

  2026cites this paper
• Autoimmunity in the era of immune checkpoint inhibitors: the evolving epidemiology of autoimmune diseases and the possible impact of COVID-19.

  2026cites this paper
• Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review

  2026cites this paper
• Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis.

  2026cites this paper
• Atezolizumab-induced neuromuscular syndrome mimicking myasthenia gravis in a patient with hepatocellular carcinoma – an area of concern

  2025cites this paper
• Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy

  2025cites this paper
• Case Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer

  2025cites this paper
• Tislelizumab-induced hemophagocytic lymphohistiocytosis in a patient with microsatellite instability-high colon cancer and coexisting systemic lupus erythematosus: a case report and literature review

  2025cites this paper
• Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease

  2025cites this paper
• Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma

  2025cites this paper
• METRN modulates immune escape via CD8+ T cells in breast cancer progression through IL-6 signaling pathway

  2025cites this paper
• Hypophysitis Associated with Immune Checkpoint Inhibitors.

  2025cites this paper
• Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project

  2025cites this paper
• Tight competition for the first-line treatment of Hodgkin’s lymphoma: a comprehensive review of practice-changing developments in recent years

  2025cites this paper
• PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers.

  2025cites this paper
• Monoclonal antibodies as adjuvant therapies for resected melanoma

  2025influential citation
• Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy

  2025cites this paper
• Blocking the IL-6 pathway to treat immune checkpoint inhibitor-induced inflammatory arthritis (Review)

  2025cites this paper
• Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention

  2025cites this paper
• Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report

  2025cites this paper
• Metastatic Malignancy Masquerading as Skin Rash

  2025cites this paper
• Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides

  2025cites this paper
• Balancing Risks and Benefits of Immune Checkpoint Inhibitors in Patients with Pre-existing Immune-Mediated Inflammatory Diseases: A Comprehensive Review.

  2025cites this paper
• Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024)

  2025influential citation
• Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs).

  2025cites this paper
• Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis

  2025cites this paper
• Immune checkpoint inhibitor-induced inflammatory arthritis vs rheumatoid arthritis: A comparative review.

  2025cites this paper
• Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases

  2025cites this paper
• Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma

  2025cites this paper
• Preexisting ulcerative colitis increases the risk of immune-related colitis and predicts divergent survival outcomes in gastrointestinal cancer patients treated with immune checkpoint inhibitors

  2025cites this paper
• Implications of glucocorticoid-induced co-inhibitory molecule expression on combined glucocorticoid and immune checkpoint inhibitor therapy

  2025cites this paper
• Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic

  2025cites this paper
• [Autoimmune diseases and immunotherapies].

  2025cites this paper
• Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.

  2025cites this paper
• Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)

  2025cites this paper
• Case Report: Severe Immune‐Related Adverse Event Under Pembrolizumab Therapy for Discoid Lupus Erythematosus‐Related Squamous Cell Carcinoma

  2025cites this paper
• Imaging Findings of Complications of New Anticancer Drugs

  2025cites this paper
• Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study

  2025cites this paper
• Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients

  2025cites this paper
• Safe Use of Immune Checkpoint Inhibitors in Patients With Autoimmune Disease in a Community Hospital Setting: A Report of Two Cases

  2025cites this paper
• Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review

  2025cites this paper
• Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer and Autoimmune Diseases

  2025influential citation
• Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review

  2025cites this paper
• Immunotherapy for hepatocellular carcinoma

  2025cites this paper
• Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis

  2025cites this paper
• Rheumatic Immune-Related Adverse Events in Patients with Metastatic Melanoma: Insights for Treatment from a Single Cancer Center

  2025cites this paper
• Complete Remission With Fourth-Line Immunotherapy After Chemotherapy Failure in a Lung Cancer Patient With Severe Autoimmune Disease: An Unexpected Turn in Oncologic Management

  2025cites this paper
• Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis.

  2025cites this paper
• Immune‐related adverse events in immune checkpoint inhibitor therapy for cancer

  2025cites this paper
• Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions

  2024cites this paper
• Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment

  2024cites this paper
• Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma.

  2024cites this paper
• Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors

  2024cites this paper
• Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report

  2024cites this paper
• Immunotherapy-induced hepatitis in metastatic colorectal cancer: a systematic review and meta-analysis

  2024cites this paper
• Discovery and optimization of 3‐(indolin‐5‐yloxy)pyridin‐2‐amine derivatives as potent necroptosis inhibitors

  2024cites this paper
• Identification of a signature of histone modifiers in kidney renal clear cell carcinoma

  2024cites this paper
• Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients

  2024cites this paper
• Adverse effects of anti-cancer biologics on the ocular surface

  2024cites this paper
• Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review

  2024cites this paper
• Toxicity in the era of immune checkpoint inhibitor therapy

  2024cites this paper
• Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids

  2024cites this paper
• Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications

  2024cites this paper
• Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).

  2024cites this paper
• Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis

  2024cites this paper
• Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.

  2024cites this paper
• Research Progress of Natural Active Substances with Immunosuppressive Activity

  2024cites this paper
• Immuncheckpointinhibitoren bei Autoimmunerkrankungen

  2024cites this paper
• Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study

  2024cites this paper
• Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis

  2024cites this paper
• Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations

  2024cites this paper
• Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions.

  2024cites this paper
• The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.

  2024cites this paper
• Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression.

  2024cites this paper
• Efficacy of Immune Checkpoint Inhibitors Combinations as First-Line Systemic Treatment in Patients with Advanced Urothelial Carcinoma: A Systematic Review and Network Meta-Analysis.

  2024cites this paper
• Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy

  2024cites this paper
• Immune Checkpoint Inhibitor Is Associated with Improved Survival in Advanced Non-small Cell Lung Cancer Occurring in Patients with Autoimmune Disease.

  2024cites this paper
• Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

  2024cites this paper
• Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report

  2024cites this paper
• Haemophagocytic Lymphohistiocytosis Following the anti-PD-1 Nivolumab in a Patient with Gastric Cancer and Ankylosing Spondylitis

  2024cites this paper
• Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy

  2024influential citation
• Immune-Related Adverse Events of Immune Checkpoint Inhibitors

  2024cites this paper
• Metastatic Melanoma Treatment in Special Populations

  2024cites this paper
• Identification of shared mechanisms and targets between immune checkpoint inhibitor-associated myocarditis and autoimmune myocarditis

  2024cites this paper
• Novel uses of complement inhibitors in myasthenia gravis—Two case reports

  2024cites this paper
• Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society

  2024cites this paper
• Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta‐analysis

  2024cites this paper
• When should we use it? The role of brentuximab vedotin in 2024.

  2024cites this paper
• Safety profiles in the use of immune checkpoint inhibitors by patients with cancer and pre-existing autoimmune diseases.

  2024cites this paper
• Dendritic Cell-Targeted Nanoparticles Enhance T Cell Activation and Antitumor Immune Responses by Boosting Antigen Presentation and Blocking PD-L1 Pathways.

  2024cites this paper
• First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

  2024cites this paper
• An underrecognized association: immune checkpoint inhibitor-related aortitis, a case report with the review of the literature

  2024cites this paper
• Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study.

  2024cites this paper
• Stevens‐Johnson syndrome and toxic epidermal necrolysis‐like eruptions in patients treated with immune checkpoint inhibitors: a systematic review

  2024cites this paper
• Current Concepts in Immune Checkpoint Inhibitor-Induced Arthritis

  2024cites this paper
• Exploration of the combined role of immune checkpoints and immune cells in the diagnosis and treatment of ankylosing spondylitis: a preliminary study immune checkpoints in ankylosing spondylitis

  2024cites this paper
• Use of Upadacitinib to Treat a Severe Flare-Up of Rheumatoid Arthritis During Anti-PD-1 Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Carcinoma of the Lung

  2024cites this paper
• Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series

  2024cites this paper